Fig. 4From: Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinomaCost-effectiveness acceptability curve. QALY: quality-adjusted life-year; GDP:gross domestic productBack to article page